Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers
Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $10
Morgan Stanley analyst Vikram Purohit maintains $Recursion Pharmaceuticals(RXRX.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success
Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $11
Needham analyst Gil Blum maintains $Recursion Pharmaceuticals(RXRX.US)$ with a buy rating, and adjusts the target price from $16 to $11.According to TipRanks data, the analyst has a success rate of 38
Cathie Wood's ARK Sells CareDx, Buys Recursion Pharmaceuticals Stock
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
A Quick Look at Today's Ratings for Recursion Pharmaceuticals(RXRX.US), With a Forecast Between $8 to $14
On Sep 04, major Wall Street analysts update their ratings for $Recursion Pharmaceuticals(RXRX.US)$, with price targets ranging from $8 to $14.Morgan Stanley analyst Vikram Purohit maintains with a